Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 235-250

  Tran, Huyen ^a   McRae, Simon ^a   Ginsberg, Jeffrey ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PROTOCOL; COMORBIDITY; COMPRESSION GARMENT; CONTINUOUS INFUSION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; ELDERLY CARE; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STANDARD; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHILIA; TREATMENT DURATION; TREATMENT INDICATION; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; PULMONARY EMBOLISM; STOCKINGS, COMPRESSION; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS; WARFARIN;

EID: 41749095169     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.006     Document Type: Review

References (139)

1. White R.H. The epidemiology of venous thromboembolism. Circulation 107 Suppl 1 (2003) I4-I8
2. Barritt D.W., and Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1 (1960) 1309-1312
3. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
4. Heit J.A., Silverstein M.D., Mohr D.N., et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 86 (2001) 452-463
5. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts: a phlebographic study. Acta Chir Scand 146 (1980) 267-269
6. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83 (2000) 657-660
7. Anderson Jr. F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 Suppl 1 (2003) 9-16
8. Kniffin Jr. W.D., Baron J.A., Barrett J., et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154 (1994) 861-866
9. Alikhan R., Cohen A.T., Combe S., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164 9 (2004) 963-968
10. Oger E., Bressollette L., Nonent M., et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 88 (2002) 592-597
11. Huisman M.V., Buller H.R., ten Cate J.W., et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 95 (1989) 498-502
12. Doyle D.J., Turpie A.G., Hirsh J., et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. Ann Intern Med 107 (1987) 441-445
13. Girard P., Musset D., Parent F., et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 116 (1999) 903-908
14. Hull R.D., Hirsh J., Carter C.J., et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 98 (1983) 891-899
15. Hull R.D., Raskob G.E., Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315 (1986) 1109-1114
16. Lagerstedt C.I., Olsson C.G., Fagher B.O., et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2 (1985) 515-518
17. Brandjes D.P., Heijboer H., Buller H.R., et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327 (1992) 1485-1489
18. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 188S-203S
19. Hommes D.W., Bura A., Mazzolai L., et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 116 (1992) 279-284
20. Basu D., Gallus A., Hirsh J., et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287 (1972) 324-327
21. Brill-Edwards P., Ginsberg J.S., Johnston M., et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 119 (1993) 104-109
22. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 119 (1993) 874-881
23. Chiu H.M., Hirsh J., Yung W.L., et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49 (1977) 171-184
24. Levine M.N., Hirsh J., Gent M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154 (1994) 49-56
25. Cruickshank M.K., Levine M.N., Hirsh J., et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151 (1991) 333-337
26. Hull R.D., Raskob G.E., Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322 (1990) 1260-1264
27. Hull R.D., Raskob G.E., Brant R.F., et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157 (1997) 2562-2568
28. Anand S.S., Bates S., Ginsberg J.S., et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 159 (1999) 2029-2032
29. Anand S., Ginsberg J.S., Kearon C., et al. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 156 (1996) 1677-1681
30. Levine M.N., Raskob G., Beyth R.J., et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 287S-310S
31. Anand S.S., Yusuf S., Pogue J., et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 107 (2003) 2884-2888
32. Beyth R.J., and Landefeld C.S. Anticoagulants in older patients: a safety perspective. Drugs Aging 6 (1995) 45-54
33. Jick H., Slone D., Borda I.T., et al. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 279 (1968) 284-286
34. Walker A.M., and Jick H. Predictors of bleeding during heparin therapy. JAMA 244 (1980) 1209-1212
35. Vieweg W.V., Piscatelli R.L., Houser J.J., et al. Complications of intravenous administration of heparin in elderly women. JAMA 213 (1970) 1303-1306
36. Glazier R.L., and Crowell E.B. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 236 (1976) 1365-1367
37. Nelson P.H., Moser K.M., Stoner C., et al. Risk of complications during intravenous heparin therapy. West J Med 136 (1982) 189-197
38. Holm H.A., Abildgaard U., and Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 53 (1985) 278-281
39. Mant M.J., O'Brien B.D., Thong K.L., et al. Haemorrhagic complications of heparin therapy. Lancet 1 (1977) 1133-1135
40. Campbell N.R., Hull R.D., Brant R., et al. Aging and heparin-related bleeding. Arch Intern Med 156 (1996) 857-860
41. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
42. Dolovich L.R., Ginsberg J.S., Douketis J.D., et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160 (2000) 181-188
43. White R.H., and Ginsberg J.S. Low-molecular-weight heparins: are they all the same?. Br J Haematol 121 (2003) 12-20
44. van der Heijden J.F., Prins M.H., and Buller H.R. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same?. Thromb Res 100 (2000) V121-V130
45. Couturaud F., Julian J.A., and Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost 86 (2001) 980-984
46. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 87 (2002) 163-164
47. Nagge J., Crowther M., and Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 162 (2002) 2605-2609
48. Gouin-Thibault I., Pautas E., and Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 28 (2005) 333-349
49. Gould M.K., Dembitzer A.D., Doyle R.L., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130 (1999) 800-809
50. Mismetti P., Laporte-Simitsidis S., Navarro C., et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 79 (1998) 1162-1165
51. Chow S.L., Zammit K., West K., et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 43 (2003) 586-590
52. Siguret V., Pautas E., Fevrier M., et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84 (2000) 800-804
53. Pautas E., Gouin I., Bellot O., et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 25 (2002) 725-733
54. Cestac P., Bagheri H., Lapeyre-Mestre M., et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 26 (2003) 197-207
55. Siguret V., Pautas E., and Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med 10 (2004) 366-370
56. Walenga J.M., Jeske W.P., Bara L., et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 86 (1997) 1-36
57. Choay J., Lormeau J.C., Petitou M., et al. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci 370 (1981) 644-649
58. Donat F., Duret J.P., Santoni A., et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41 Suppl 2 (2002) 1-9
59. Boneu B., Necciari J., Cariou R., et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74 (1995) 1468-1473
60. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
61. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
62. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 (2003) 535-555
63. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 311S-337S
64. Forster A.J., and Wells P.S. The rationale and evidence for the treatment of lower-extremity deep venous thrombosis with thrombolytic agents. Curr Opin Hematol 9 (2002) 437-442
65. Dalen J.E., Alpert J.S., and Hirsh J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated?. Arch Intern Med 157 (1997) 2550-2556
66. Jerjes-Sanchez C., Ramirez-Rivera A., de Lourdes Garcia M., et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 2 (1995) 227-229
67. Meneveau N., Bassand J.P., Schiele F., et al. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. J Am Coll Cardiol 22 (1993) 1075-1079
68. Gisselbrecht M., Diehl J.L., Meyer G., et al. Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: a comparison with non-elderly patients. J Am Geriatr Soc 44 (1996) 189-193
69. Mikkola K.M., Patel S.R., Parker J.A., et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 134 (1997) 69-72
70. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
71. Prins M.H., Hutten B.A., Koopman M.M., et al. Long-term treatment of venous thromboembolic disease. Thromb Haemost 82 (1999) 892-898
72. Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307 (1982) 1676-1681
73. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
74. Rosove M.H., and Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
75. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003) 1133-1138
76. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005) 848-853
77. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 (2003) 631-639
78. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126 (1997) 133-136
79. Crowther M.A., Ginsberg J.B., Kearon C., et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 159 (1999) 46-48
80. Kovacs M.J., Rodger M., Anderson D.R., et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial. Ann Intern Med 138 (2003) 714-719
81. Kovacs M.J., Cruickshank M., Wells P.S., et al. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis 28 (1998) 62-69
82. O'Connell M.B., Kowal P.R., Allivato C.J., et al. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 20 (2000) 923-930
83. Gage B.F., Fihn S.D., and White R.H. Management and dosing of warfarin therapy. Am J Med 109 (2000) 481-488
84. Landefeld C.S., and Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87 (1989) 144-152
85. Beyth R.J., Quinn L.M., and Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105 (1998) 91-99
86. Ageno W., and Turpie A.G. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 84 (1999) 905-908
87. Mungall D., and White R. Aging and warfarin therapy. Ann Intern Med 117 (1992) 878-879
88. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
89. Agnelli G., Prandoni P., Santamaria M.G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345 (2001) 165-169
90. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
91. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 (1993) 315-328
92. White R.H., Beyth R.J., Zhou H., et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 107 (1999) 414-424
93. Linkins L.A., Choi P.T., and Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139 (2003) 893-900
94. Pengo V., Legnani C., Noventa F., et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 85 (2001) 418-422
95. Gurwitz J.H., Goldberg R.J., Holden A., et al. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 148 (1988) 1733-1736
96. Wickramasinghe L.S., Basu S.K., and Bansal S.K. Long-term oral anticoagulant therapy in elderly patients. Age Ageing 17 (1988) 388-396
97. Forfar J.C. Prediction of hemorrhage by during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J 103 (1982) 445-446
98. Launbjerg J., Egeblad H., Heaf J., et al. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 229 (1991) 351-355
99. Wittkowsky A.K., Whitely K.S., Devine E.B., et al. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy 24 (2004) 600-605
100. McCormick D., Gurwitz J.H., Goldberg R.J., et al. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. J Thromb Thrombolysis 7 (1999) 157-163
101. Ryan P.J., Gilbert M., and Rose P.E. Computer control of anticoagulant dose for therapeutic management. BMJ 299 (1989) 1207-1209
102. Wyld P.J., West D., and Wilson T.H. Computer dosing in anticoagulant clinics: the way forward?. Clin Lab Haematol 10 (1988) 235-236
103. Ryan P.J., Gilbert M., and Rose P.E. Computer control of anticoagulant dose for therapeutic management. BMJ 299 (1989) 1207-1209
104. Poller L., Wright D., and Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 46 (1993) 299-303
105. Poller L., Shiach C.R., MacCallum P.K., et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 352 (1998) 1505-1509
106. Cromheecke M.E., Levi M., Colly L.P., et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 356 (2000) 97-102
107. Ansell J., Hirsh J., Dalen J., et al. Managing oral anticoagulant therapy. Chest 119 1 Suppl (2001) 22S-38S
108. Kuijer P.M., Hutten B.A., Prins M.H., et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159 (1999) 457-460
109. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
110. Hull R., Pineo G.F., and Mah A. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. [abstract]. Blood 100 (2002) 148a
111. van der Heijden M.H., Hutten B.A., Buller H., et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of systematic venous thromboembolism. Cochrane Database Syst Rev 3 (2001) CD002001
112. Veiga F., Escriba A., Maluenda M.P., et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84 (2000) 559-564
113. Luk C., Wells P.S., Anderson D., et al. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111 (2001) 270-273
114. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338 (1998) 409-415
115. Schulman S., Wahlander K., Lundstrom T., et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
116. Fiessinger J.N., Huisman M.V., Davidson B.L., et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293 (2005) 681-689
117. Buller H.R., Cohen A.T., Davidson B., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 11 (2007) 1094-1104
118. Brandjes D.P., Buller H.R., Heijboer H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997) 759-762
119. Prandoni P. Below-knee compression stockings for prevention of the post-thrombotic syndrome: a randomized study. [abstract]. Pathophysiol Haemost Thromb 32 Suppl 2 (2002) 72
120. Prandoni P., Lensing A.W., Prins M.H., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004) 249-256
121. Kearon C., Ginsberg J.S., Anderson D.R., et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2 (2004) 743-749
122. Sudlow M.F., Campbell I.A., Angel J.H., et al. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 340 (1992) 873-876
123. Levine M.N., Hirsh J., Gent M., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74 (1995) 606-611
124. Pinede L., Ninet J., Duhaut P., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103 (2001) 2453-2460
125. Baglin T., Luddington R., Brown K., et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523-526
126. Agnelli G., Prandoni P., and Becattini C. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139 (2003) 19-25
127. Schulman S., Svenungsson E., and Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104 (1998) 332-338
128. Schulman S., Granqvist S., Holmstrom M., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336 (1997) 393-398
129. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
130. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
131. Kearon C., Crowther M., and Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51 (2000) 169-185
132. Lindmarker P., Schulman S., Sten-Linder M., et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 81 (1999) 684-689
133. Eichinger S., Stumpflen A., Hirschl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80 (1998) 566-569
134. White R.H., Zhou H., and Romano P.S. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 158 (1998) 1005-1010
135. Heit J.A., Mohr D.N., Silverstein M.D., et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160 (2000) 761-768
136. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 110 Suppl 1 (2004) I10-I18
137. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
138. Douketis J.D., Kearon C., Bates S., et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279 (1998) 458-462
139. Simioni P., Prandoni P., Lensing A.W., et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96 (2000) 3329-3333